Aadi Bioscience Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Dave Lennon

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	2.7yrs

Actualizaciones recientes de la dirección

Recent updates

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

CEO

Dave Lennon (52 yo)

less than a year

Permanencia

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Neil Desai	Founder	12.5yrs	US$3.05m	8.19% $ 3.5m
Loretta Itri	Chief Medical Officer	2.5yrs	US$1.66m	0.012% $ 5.3k
David Lennon	President	less than a year	sin datos	sin datos
Scott Giacobello	CFO, Treasurer	2.4yrs	US$4.47m	0.081% $ 35.0k
Stephen Rodin	Senior VP of Legal & General Counsel	2.2yrs	sin datos	sin datos
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	1.8yrs	sin datos	sin datos
Bryan Ball	Chief Quality Officer & Senior VP of Manufacturing Operations	1.7yrs	sin datos	sin datos

2.2yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AADI se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Neil Desai	Founder	12.5yrs	US$3.05m	8.19% $ 3.5m
David Lennon	President	less than a year	sin datos	sin datos
Caley Castelein	Independent Director	2.7yrs	US$252.00k	0.080% $ 34.5k
Emma Reeve	Independent Director	2.6yrs	US$240.00k	0% $ 0
Anupam Dalal	Independent Director	2.7yrs	US$235.00k	0.0046% $ 2.0k
Karin Hehenberger	Independent Director	2.7yrs	US$282.50k	0% $ 0
Richard Maroun	Independent Director	7.2yrs	US$240.00k	0% $ 0
Mohammad Hirmand	Independent Director	1.1yrs	sin datos	sin datos
Behzad Aghazadeh	Independent Director	2.7yrs	US$224.50k	0% $ 0

2.7yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de AADI no se considera experimentada (2.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Aadi Bioscience Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Recent updates

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Price target decreased by 67% to US$11.67

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Founder notifies of intention to sell stock

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

New minor risk - Share price stability

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: EPS misses analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$38.75

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

Founder notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 112%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Interim Chief Financial Officer Lance Thibault has left the company

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad